Literature DB >> 8877025

Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration.

K M Sowinski1, J J Lima, B S Burlew, J D Massie, J A Johnson.   

Abstract

1. Racial differences in propranolol enantiomer kinetics following oral dosing were previously documented in our laboratory. The purpose of this study was to more completely describe propranolol kinetics in black and white subjects with the goal of gaining a better understanding of the mechanism(s) responsible for racial differences in oral propranolol kinetics. 2. Twelve white and 13 black healthy males were included in the study. Poor metabolizers of dextromethorphan and mephenytoin were excluded. Subjects took oral propranolol 80 mg every 8 h for 16 doses and received an intravenous dose of radiolabelled propranolol with the 16th dose. Serum and urine samples were collected for 24 h after the 16th dose. Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites). 4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05). 5. There were trends (P > 0.05 < 0.10) toward higher side chain oxidation, 4-hydroxylation and R-propranolol glucuronidation in blacks compared with whites. Ethnic differences in the enantiomeric ratios of partial metabolic clearance values were not observed. 6. We conclude the higher propranolol oral clearances in black subjects are explained by blacks having slightly higher hepatic metabolism via all three of its major metabolic pathways. Higher propranolol clearances among black subjects were also observed and we conclude this finding is explained largely by the higher hepatic metabolism, but also by slightly higher liver blood flow among black subjects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877025      PMCID: PMC2042685          DOI: 10.1046/j.1365-2125.1996.03879.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

Review 1.  Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.

Authors:  William H Frishman; Mamata Alwarshetty
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects.

Authors:  Lian-Jun Luan; Qing Shao; Jian-Yin Ma; Su Zeng
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

4.  Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.

Authors:  Charles D Howell; Thomas C Dowling; Marika Paul; Abdus S Wahed; Norah A Terrault; Milton Taylor; Lennox Jeffers; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04-14       Impact factor: 11.382

Review 5.  Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.

Authors:  Lizzy M Brewster; Yackoob K Seedat
Journal:  BMC Med       Date:  2013-05-30       Impact factor: 8.775

6.  Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol.

Authors:  Ebrahim Salehifar; Shima Ebrahim; Mohammad-Reza Shiran; Fatemeh Faramarzi; Hossein Askari Rad; Razieh Avan; Asadollah Mohseni Kiasari; Pouneh Ebrahimi
Journal:  Adv Pharm Bull       Date:  2017-06-30

7.  Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?

Authors:  Olusola Olafuyi; Nikita Parekh; Jacob Wright; Jennifer Koenig
Journal:  Pharmacol Res Perspect       Date:  2021-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.